Anavex Life Sciences Corp (AVXL)

[falconer66a]

For Approval, SOC Must Only Be Exceeded

Our other patients declined but did they decline less than those on the soc.

Yes, sure would be nice if Anavex 2-73 brought continuing relief to any and all with Alzheimer's, without diminished effects after long periods of treatment.

But, neither of those desired outcomes may happen. Anavex 2-73 may provide continuing symptomatic relief for only a portion of those with Alzheimer's. And, for some, it might begin to fail after certain dosing periods.

But in order for the drug to get approved, it simply has to work better than the existing standard of care. That's a low hurdle to leap. The existing Alzheimer's SOC drugs hold things or slightly improve them only for a few weeks to a few months or so. Then, everything returns, in the wrong direction.

Facts are these. None of the animal or human trials with Anavex 2-73 predict equal or reduced treatment outcomes, compared to the standard of care drugs already on the market. Anavex 2-73 is better. Stronger support or increase of cognition, for enduring periods of time. No evidence to even suggest Anavex 2-73 won't be approved. It's safe, and it works better, provides more desirable outcomes, than any presently-approved drug.